Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BNTX NYSE:GSK NYSE:JNJ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNTXBioNTech$91.99-0.3%$95.14$79.52▼$124.00$23.32B1.36947,309 shs646,501 shsGSKGSK$50.91-0.2%$54.47$35.45▼$61.69$103.47B0.384.24 million shs3.53 million shsJNJJohnson & Johnson$230.61+0.1%$235.49$147.33▼$251.71$554.67B0.277.67 million shs6.97 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNTXBioNTech-1.53%-3.18%-4.62%-12.79%-2.40%GSKGSK+0.11%+0.74%-13.57%-12.92%+40.11%JNJJohnson & Johnson+2.67%+2.65%-3.18%-5.77%+54.95%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNTXBioNTech$91.99-0.3%$95.14$79.52▼$124.00$23.32B1.36947,309 shs646,501 shsGSKGSK$50.91-0.2%$54.47$35.45▼$61.69$103.47B0.384.24 million shs3.53 million shsJNJJohnson & Johnson$230.61+0.1%$235.49$147.33▼$251.71$554.67B0.277.67 million shs6.97 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNTXBioNTech-1.53%-3.18%-4.62%-12.79%-2.40%GSKGSK+0.11%+0.74%-13.57%-12.92%+40.11%JNJJohnson & Johnson+2.67%+2.65%-3.18%-5.77%+54.95%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBNTXBioNTech 2.72Moderate Buy$130.6041.97% UpsideGSKGSK 1.90Reduce$53.004.11% UpsideJNJJohnson & Johnson 2.74Moderate Buy$253.049.73% UpsideCurrent Analyst Ratings BreakdownLatest JNJ, BNTX, and GSK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2026JNJJohnson & Johnson Johnson RiceSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Outperform5/13/2026JNJJohnson & Johnson Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$265.005/12/2026BNTXBioNTech Berenberg BankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$155.00 ➝ $140.005/6/2026BNTXBioNTech Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$171.00 ➝ $158.005/6/2026BNTXBioNTech Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$150.00 ➝ $140.005/1/2026GSKGSK Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C+) ➝ Buy (B)4/27/2026BNTXBioNTech HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$130.004/24/2026JNJJohnson & Johnson Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B+) ➝ Buy (B)4/20/2026JNJJohnson & Johnson GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$244.00 ➝ $266.004/16/2026JNJJohnson & Johnson ArgusSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$240.00 ➝ $275.004/16/2026JNJJohnson & Johnson Daiwa Securities GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$237.00 ➝ $246.00(Data available from 5/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBNTXBioNTech$2.81B8.29$1.31 per share70.15$86.54 per share1.06GSKGSK$32.78B3.15$6.00 per share8.48$11.57 per share4.40JNJJohnson & Johnson$94.19B5.89$14.52 per share15.88$33.73 per share6.84Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBNTXBioNTech-$1.29B-$5.88N/AN/AN/A-44.39%-5.30%-4.62%N/AGSKGSK$7.54B$3.8513.239.902.5917.82%44.28%11.49%7/29/2026 (Estimated)JNJJohnson & Johnson$26.80B$8.6526.6618.332.2021.83%32.60%13.29%7/15/2026 (Estimated)Latest JNJ, BNTX, and GSK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/4/2026Q1 2026BNTXBioNTech-$2.52-$2.2570+$0.2630-$2.43$207.42 million$136.59 million4/14/2026Q1 2026JNJJohnson & Johnson$2.68$2.70+$0.02$2.14$23.60 billion$24.06 billion2/14/2026Q4 2025BNTXBioNTechN/A-$0.3870N/A-$1.47N/A$1.06 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBNTXBioNTech$1.531.66%N/AN/A N/AGSKGSK$1.813.56%-7.86%47.01%N/AJNJJohnson & Johnson$5.202.25%+5.25%60.12%64 YearsLatest JNJ, BNTX, and GSK DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/29/2026GSKGSKquarterly$0.443.36%5/15/20265/15/20267/9/20264/14/2026JNJJohnson & Johnsonquarterly$1.342.23%5/26/20265/26/20266/9/20261/1/2100GSKGSKquarterly$0.42064.3%8/15/20258/15/202510/9/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBNTXBioNTech0.018.808.74GSKGSK0.800.790.52JNJJohnson & Johnson0.461.030.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBNTXBioNTech15.52%GSKGSK15.74%JNJJohnson & Johnson69.55%Insider OwnershipCompanyInsider OwnershipBNTXBioNTech19.20%GSKGSK10.00%JNJJohnson & Johnson0.16%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBNTXBioNTech7,807252.88 million204.33 millionOptionableGSKGSK66,8412.03 billion1.83 billionOptionableJNJJohnson & Johnson138,2002.41 billion2.40 billionOptionableJNJ, BNTX, and GSK HeadlinesRecent News About These CompaniesGroundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, underscoring urgency for continued innovation3 hours ago | finance.yahoo.comGroundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, underscoring urgency for continued innovationMay 14 at 4:01 PM | prnewswire.comWhy Is Johnson & Johnson (JNJ) Down 3.5% Since Last Earnings Report?May 14 at 12:31 PM | zacks.comLeerink Partners upgrades Johnson & Johnson (JNJ)May 14 at 9:14 AM | msn.comMeiraGTx Reports First Quarter 2026 Financial and Operational ResultsMay 14 at 9:14 AM | finance.yahoo.comCAPLYTA Data Highlights Johnson & Johnson Valuation And Mental Health StoryMay 14 at 9:14 AM | finance.yahoo.comSummit Wealth Group LLC Co. Sells 5,308 Shares of Johnson & Johnson $JNJMay 14 at 5:38 AM | marketbeat.comMadison Asset Management LLC Decreases Stock Position in Johnson & Johnson $JNJMay 14 at 5:21 AM | marketbeat.comJohnson & Johnson (NYSE:JNJ) Upgraded to "Outperform" at Leerink PartnersMay 14 at 4:59 AM | americanbankingnews.comBank Julius Baer & Co. Ltd Zurich Raises Stock Position in Johnson & Johnson $JNJMay 14 at 4:14 AM | marketbeat.comJohnson & Johnson $JNJ Shares Acquired by Atria Investments IncMay 14 at 3:20 AM | marketbeat.comJohnson & Johnson $JNJ Shares Acquired by Allworth Financial LPMay 14 at 3:03 AM | marketbeat.comJohnson & Johnson Gains Spotlight In S&P 500 Index RallyMay 13 at 11:50 PM | kalkinemedia.comKJohnson & Johnson (NYSE:JNJ) Shares Up 2.8% on Analyst UpgradeMay 13 at 5:14 PM | marketbeat.comWhy Is Johnson & Johnson Trending Right NowMay 13 at 1:48 PM | kalkinemedia.comKJohnson & Johnson upgraded at Leerink on growth prospectsMay 13 at 1:48 PM | seekingalpha.comJNJ gets Wall Street boost as blockbuster drug bets ignite growth hopesMay 13 at 1:48 PM | finance.yahoo.comRussell 1000 Dividend ETF Hits $125 as Johnson & Johnson Leads The Safety TestMay 13 at 9:10 AM | 247wallst.comRussell 1000 Dividend ETF Hits $125 as Johnson & Johnson Leads The Safety TestMay 13 at 9:01 AM | 247wallst.comThe 2 US Companies With a Better Credit Rating Than Uncle Sam Belong in Every Retirement PortfolioMay 13 at 8:47 AM | 247wallst.comThe 2 US Companies With a Better Credit Rating Than Uncle Sam Belong in Every Retirement PortfolioMay 13 at 8:15 AM | 247wallst.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 20265 Stocks Positioned to Win the AI Data Center BuildoutBy Bridget Bennett | April 20, 2026NVIDIA's Quantum Computing Play Just Sent IonQ and Rigetti Flying By Jeffrey Neal Johnson | April 15, 2026AMD’s Breakout Isn’t the Story—This Catalyst IsBy Thomas Hughes | April 24, 2026The Most Important Part of These 3 Big Pharma Earnings Reports Wasn’t the BeatBy Jessica Mitacek | May 2, 2026JNJ, BNTX, and GSK Company DescriptionsBioNTech NASDAQ:BNTX$91.99 -0.24 (-0.26%) Closing price 04:00 PM EasternExtended Trading$92.00 +0.01 (+0.01%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.GSK NYSE:GSK$50.91 -0.08 (-0.16%) Closing price 03:59 PM EasternExtended Trading$50.91 0.00 (0.00%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.Johnson & Johnson NYSE:JNJ$230.61 +0.19 (+0.08%) Closing price 03:59 PM EasternExtended Trading$230.25 -0.36 (-0.16%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas YETI Rallies After Earnings Beat and Raised Outlook Cisco’s Vertical Rally May Still Be in the Early Innings Dividend Growth or High Yield: The Income Investor's Bet Nebius Upside Expands as AI Feedback Loop Intensifies Oklo Stock Could Be Ready for Another Massive Run Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell Qualcomm Stock Doubles: New Era? Or Another False Start? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
